By monitoring Loss of Exclusivity (LOE) forecasts and performing white space analysis, facilities can identify therapeutic areas with high demand but low patent density, or identify when specific formulation patents expire, allowing for the legal production of non-infringing compounds
This is an environment thats not going to be going away anytime soon, said Nicole Faucher, president of Clearway Health, a Boston Medical Center subsidiary that supports specialty pharmacies
PSM joined three other organizations for a sign-on letter explaining our concerns that unrestricted mass compounding increases the untraceable drug supply
No, taking your medication early will not accelerate your weight loss results
The programs cost may prove to be a limiting factor
Full assessment of how quickly semaglutide produces results varies by condition and individual response